Status:
COMPLETED
Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Metabolic Syndrome X
Eligibility:
All Genders
45+ years
Brief Summary
To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.
Eligibility Criteria
Inclusion
- Age \> 45 years
- Increased waist circumference (\>88.9cm \[\>35in\] men, \>78.7cm \[\>31in\] for women)
- Elevated triglycerides (\>150mg/dl)
- Low HDL cholesterol (\<40mg/dl in men, \<50mg/dl in women)
- Hypertension (\>130/\>85mmHG)
- Impaired fasting glucose (\>110mg/dl) (8)
- Hypertensive patient assessed to benefit from telmisartan based treatment
Exclusion
- Hypersensitivity to telmisartan, hydrochlorothiazide (HCTZ) and its excipients
- \<3 months myocardial infarction (MI), stroke or severe heart failure
Key Trial Info
Start Date :
June 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
15268 Patients enrolled
Trial Details
Trial ID
NCT00613314
Start Date
June 1 2007
Last Update
May 26 2014
Active Locations (122)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Alaminos City, Pangasinan, Philippines
2
Boehringer Ingelheim Investigational Site
Angeles City, Philippines
3
Boehringer Ingelheim Investigational Site
Angeles City, Pampanga, Philippines
4
Boehringer Ingelheim Investigational Site
Antipolo City, Rizal, Philippines